The present invention refers to a device comprising polytetrafluorethylene (PTFE) filters and the use of the same for collecting, detecting and identifying organisms present in air ecosystems. The invention also provides a method suitable for the capture, detection and identification of whole airborne biological particles, including viruses and other important air pathogens, which involves the use of the device. This method allows toperform organism, preferably viral, metagenomics to sequence all DNA and RNA organisms captured in the filters. This methodology may be used to detect, for instance, SARS-CoV2 particles in air samples.

The present invention refers to a device comprising polytetrafluorethylene (PTFE) filters and the use of the same for collecting, detecting and identifying organisms present in air ecosystems. The invention also provides a method suitable for the capture, detection and identification of whole airborne biological particles, including viruses and other important air pathogens, which involves the use of the device. This method allows toperform organism, preferably viral, metagenomics to sequence all DNA and RNA organisms captured in the filters. This methodology may be used to detect, for instance, SARS-CoV2 particles in air samples.

The present invention refers to a device comprising polytetrafluorethylene (PTFE) filters and the use of the same for collecting, detecting and identifying organisms present in air ecosystems. The invention also provides a method suitable for the capture, detection and identification of whole airborne biological particles, including viruses and other important air pathogens, which involves the use of the device. This method allows toperform organism, preferably viral, metagenomics to sequence all DNA and RNA organisms captured in the filters. This methodology may be used to detect, for instance, SARS-CoV2 particles in air samples.

Provided is a composition for detecting mutations of 2019 novel coronavirus mutation. Also provided are a kit containing the composition, the use of the composition, and a method for detecting mutations of 2019 novel coronavirus.

The invention relates to the technical field of nucleic acid detection and discloses a novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes a COVID-19 reaction solution, wherein the COVID-19 reaction solution is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORFlab section probe, an N section probe and an E section probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.

The invention relates to the technical field of nucleic acid detection and discloses a novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes a COVID-19 reaction solution, wherein the COVID-19 reaction solution is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORFlab section probe, an N section probe and an E section probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.

The medical field of COVID-19 diagnosis relates to methods for detecting SARS-CoV-2 nucleic acids in a sample as well as combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.

The medical field of COVID-19 diagnosis relates to methods for detecting SARS-CoV-2 nucleic acids in a sample as well as combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.

The present invention provides methods for high throughput screening and detection of nucleic acids from pathogens, such as SARS CoV-2, using nucleic acid amplification with nanoparticle binding complex formation and MRI or NMR detection. In certain embodiments, the MRI is three-dimensional MRI that simultaneously detects a plurality of amplified nucleic acid-nanoparticle complexes. In certain embodiments, the nucleic acids are amplified by isothermal LAMP techniques. In other embodiments, the nucleic acids are amplified by PCR. Methods of the invention are particularly useful rapid screening of large number of samples during pandemic situations.

The present invention includes compositions and methods for the detection of all known respiratory agents including Coronaviruses, and the recently discovered Sars-CoV-2, the agent of the CoVID Pandemic. The invention further includes detection of immune signatures of patients infected with a Coronavirus as well as other infectious agents.